mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27
Metrics: PDF 1262 views | HTML 2019 views | ?
Zhuoying Feng1,*, Luping Zhang1,*, Junchen Zhou1, Shuai Zhou1, Li li1, Xuyan Guo1, Guoying Feng1, Ze Ma1, Wenhua Huang2, Fei Huang1
1Institute of Human Anatomy and Histology and Embryology, Otology & Neuroscience Center, Binzhou Medical University, Laishan District, Shandong Province, 264003,China
2Institute of Clinical Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
*These authors contributed to this work equally and should be considered as co-first authors
Fei Huang, email: email@example.com
Wenhua Huang, email: firstname.lastname@example.org
Keywords: gliomas, mir-218-2, CDC27, proliferation, invasion
Received: December 28, 2015 Accepted: November 02, 2016 Published: December 10, 2016
Glioma has become a significant global health problem with substantial morbidity and mortality, underscoring the importance of elucidating its underlying molecular mechanisms. Recent studies have identified mir-218 as an anti-oncogene; however, the specific functions of mir-218-1 and mir-218-2 remain unknown, especially the latter. The objective of this study was to further investigate the role of mir-218-2 in glioma. Our results indicated that mir-218-2 is highly overexpressed in glioma. Furthermore, we showed that mir-218-2 is positively correlated with the growth, invasion, migration, and drug susceptibility (to β-lapachone) of glioma cells. In vitro, the overexpression of mir-218-2 promoted glioma cell proliferation, invasion, and migration. In addition, the overexpression of mir-218-2 in vivo was found to increase glioma tumor growth. Accordingly, the inhibition of mir-218-2 resulted in the opposite effects. Cell division cycle 27 (CDC27), the downstream target of mir-218-2, is involved in the regulation of glioma cells. Our results indicate that the overexpression of CDC27 counteracted the function of mir-218-2 in glioma cells. These novel findings provide new insight in the application of mir-218-2 as a potential glioma treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.